NCT03162224 2022-08-25
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune LLC
Phase 1/2 Completed
MedImmune LLC
Inovio Pharmaceuticals
Inovio Pharmaceuticals